Return to content in this issue


Dupilumab as Effective Therapy for Corticosteroid- Dependent/Resistant Type 2 Inflammation-Related Cutaneous Adverse Reactions

Shen C1,2*, Wu N1,2*, Yang L1,2, Wang B3, Liu T1,2, Tao J1,2

1Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Hubei Engineering Research Center of Skin Disease Theranostics and Health, Wuhan, China
3Department of Dermatology, University of Michigan, Ann Arbor, United States
*Both authors contributed equally to this work.

J Investig Allergol Clin Immunol 2024; Vol 34(2) : 145-147
doi: 10.18176/jiaci.0944

Key words: Drug rash, Corticosteroid-resistant, Dupilumab, TH2 pathway, DRESS syndrome